• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Ritalin Could Trigger Heart Problems In Children
Ritalin and similar forms of ADHD medication may trigger abnormal heart rhythms and increase heart attack risk in some children soon after they start taking the drug, according to a new study.  This connection was especially true for children who were born with heart disease. According to the study, published in the British medical journal BMJ, kids had an increased risk of heart attack between eight and 56 days after starting methylphenidate, a stimulant most commonly sold as Ritalin, although this heightened risk didn’t reach statistical significance. The researchers could find no evidence of a heightened...
Source: Science - The Huffington Post - June 8, 2016 Category: Science Source Type: news

Methylphenidate May Increase Risk for Arrhythmias, Myocardial Infarction In Some Youth
Findings from a study published in BMJ Open Access shows that some children and adolescents who are receiving methylphenidate for treatment of attention-deficit/hyperactivity disorder (ADHD) may be at increased risk for certain adverse cardiovascular events. "Drugs to treat ADHD have been shown to be efficacious in reducing symptoms of impulsivity and hyperactivity in children,” the study authors wrote, "but concerns have been expressed about possible adverse cardiovascular events with the first-line treatment, methylphenidate."To determine whether an association exists between methylphenidate and adverse cardiovascular ...
Source: Psychiatr News - June 3, 2016 Category: Psychiatry Tags: ADHD cardiovascular risk methylphenidate youth Source Type: research